Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

BACKGROUND: Patients with relapsed or refractory (R/R) lymphomas have benefited from chimeric antigen receptor (CAR)-T-cell therapy. However, this treatment is linked to a high frequency of adverse events (AEs), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jin, Zhang, Ying, Shan, Meng, Zong, Xiangping, Geng, Hongzhi, Li, Jiaqi, Chen, Guanghua, Yu, Lei, Xu, Yang, Li, Caixia, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484486/
https://www.ncbi.nlm.nih.gov/pubmed/36131934
http://dx.doi.org/10.3389/fimmu.2022.997589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484486/
https://www.ncbi.nlm.nih.gov/pubmed/36131934
http://dx.doi.org/10.3389/fimmu.2022.997589

Ejemplares similares